Current standard-of-care for obesity and T2DM (Pahan 2006) includes lipid-lowering medications (statins, peroxisomal β pathway stimulators, intestinal cholesterol absorption inhibitors), and, before insulin injections become necessary, oral hypoglycemic agents (insulin sensitizers and secretagogues, delaying agents of gut carbohydrates absorption). The gene discussed is INS; the disease is type 2 diabetes mellitus.